関連する実験動画
Updated: Jan 8, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
875
肥満治療薬投与中の摂食行動の変化
Ming Chuen Chong1, Tak Ying Louise Ko1, Philippus L le Roux1
1Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
Clinical obesity
|December 20, 2025
まとめ
薬理学的肥満治療は食欲と食べ物への渇望を効果的に低下させる。患者は減量と維持をスペクトラムとして経験し、食事量のコントロールは長期的な行動の鍵となる。
科学分野:
- 肥満研究;行動科学;薬理学的介入
背景:
- 肥満は、複数の要因に影響される複雑な慢性疾患である。 薬理学的治療は減量を助けるが、摂食行動への長期的な影響は不明である。
研究 の 目的:
- 減量薬と、動的段階および安定段階における摂食行動に関する患者の経験を探求すること。 減量から体重維持への移行を理解すること。
主な方法:
- 31回の半構造化面接を用いた質的研究。 空腹感、満腹感、食物に関する思考、食事量、嗜好性に焦点を当てた面接のテーマ分析。
主要な成果:
- 動的段階:顕著な食欲抑制、早期満腹感、フードノイズの低減、少量での満腹感。 食事量のコントロールは、段階を通して持続的な行動変容である。 長期目標は減量から維持へと移行し、安定段階では薬剤の効果への懸念が生じる。
結論:
- 体重管理は二分法ではなくスペクトラムである。 患者中心の洞察は、臨床実践、政策、および肥満薬物療法に関する将来の研究に情報を提供できる。
関連する概念動画
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
221
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
221
Binge Eating Disorders
402
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
402
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
159
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
159
Bulimia Nervosa
641
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
641
Drug Dosing: Obese Patients
198
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
198
Regulation of Food Intake
2.2K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.2K

